Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR8 | Q9NR97 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | ESR1 | P03372 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2792249 | 0.80 | TLR8 (0.46) | TLR8ALDH1A1POLBKMT2ATSHR | |
| SCHEMBL13287470 | 0.76 | RAB9A (0.41) | TLR8ALDH1A1POLBKMT2ASMN1; SMN2 | |
| SCHEMBL25043395 | 0.75 | — | — | |
| SCHEMBL17219025 | 0.74 | TLR8 (0.49) | TLR8ALDH1A1POLBKMT2A | |
| SCHEMBL13287496 | 0.73 | TLR8 (0.37) | TLR8ALDH1A1POLBKMT2ATSHR | |
| SCHEMBL3648737 | 0.72 | — | — | |
| SCHEMBL11930756 | 0.72 | LMNA (0.39) | TLR8ALDH1A1POLBKMT2ATSHR | |
| SCHEMBL10363999 | 0.72 | TLR8 (0.50) | TLR8ALDH1A1POLBKMT2A | |
| SCHEMBL6545771 | 0.72 | TLR8 (0.50) | TLR8ALDH1A1POLBKMT2A | |
| SCHEMBL10363599 | 0.72 | TLR8 (0.50) | TLR8ALDH1A1POLBKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220411429-A1 | CONDENSED PYRIDAZINE OR PYRIMIDINE AS BTK INHIBITORS | BIOGEN MA INC. | 2022-12-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220411429-A1 | CONDENSED PYRIDAZINE OR PYRIMIDINE AS BTK INHIBITORS | BTK, CDK2, SYK | TLR8 1805/4885ALDH1A1 2770/4885POLB 885/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.